» Articles » PMID: 34171038

United States Drug Courts and Opioid Agonist Therapy: Missing the Target of Overdose Reduction

Overview
Specialty Forensic Sciences
Date 2021 Jun 25
PMID 34171038
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

•Agonist therapy for opioid use disorder (OUD) is often inaccessible in the US at a time of high overdose mortality.•OUD therapy could be offered by drug treatment courts as an alternative to criminal prosecution for some drug offenses.•Many drug courts, however, reject gold-standard agonist therapies, seeing them as "another form of addiction".•Drug courts often prefer to offer extended-release naltrexone, but it is costly and requires pre-treatment abstinence.•Drug courts have had limited success in improving access to OUD treatment at a time of high overdose mortality.

Citing Articles

Assessing the effectiveness of problem-solving courts on the reduction of overdose deaths in the United States: A difference-in-difference study.

Lindenfeld Z, Kim S, Chang J Drug Alcohol Depend Rep. 2023; 4:100088.

PMID: 36846580 PMC: 9948897. DOI: 10.1016/j.dadr.2022.100088.


Substance misuse and community supervision: A systematic review of the literature.

Sirdifield C, Brooker C, Marples R Forensic Sci Int Mind Law. 2021; 1:100031.

PMID: 33458713 PMC: 7790447. DOI: 10.1016/j.fsiml.2020.100031.

References
1.
DeMatteo D, Marlowe D, Festinger D, Arabia P . Outcome Trajectories in Drug Court: Do All Participants Have Drug Problems?. Crim Justice Behav. 2011; 36(4):354-368. PMC: 3211110. DOI: 10.1177/0093854809331547. View

2.
Leung P, Macdonald E, Stanbrook M, Dhalla I, Juurlink D . A 1980 Letter on the Risk of Opioid Addiction. N Engl J Med. 2017; 376(22):2194-2195. DOI: 10.1056/NEJMc1700150. View

3.
Csete J, Catania H . Methadone treatment providers' views of drug court policy and practice: a case study of New York State. Harm Reduct J. 2013; 10:35. PMC: 4176483. DOI: 10.1186/1477-7517-10-35. View

4.
Binswanger I, Glanz J . Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. Drug Saf. 2018; 41(10):979-980. PMC: 6366853. DOI: 10.1007/s40264-018-0705-8. View

5.
Jarvis B, Holtyn A, Subramaniam S, Tompkins D, Oga E, Bigelow G . Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018; 113(7):1188-1209. PMC: 5993595. DOI: 10.1111/add.14180. View